<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04980105</url>
  </required_header>
  <id_info>
    <org_study_id>UOW/MS102</org_study_id>
    <nct_id>NCT04980105</nct_id>
  </id_info>
  <brief_title>Intra-articular Injections of Platelet-rich Plasma, Hyaluronic Acid, or Corticosteroids for Knee Osteoarthritis</brief_title>
  <official_title>Intra-articular Injections of Platelet-rich Plasma, Hyaluronic Acid, or Corticosteroids for Knee Osteoarthritis, Which is Better? A Prospective Study of a Single-blind Randomized Control Trial RCT From the Iraqi Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wasit</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wasit</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess if there are any differences among platelet-rich plasma, hyaluronic acid, and&#xD;
      corticosteroid knee intra-articular injection regarding function and pain.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A total of 150 participants fulfilling the inclusion criteria, patients were randomly assigned into three groups by a computer-based protocol. The patients were separated into three groups according to the type of treatment administered.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Timed Up and Go test (TUG)</measure>
    <time_frame>18th months</time_frame>
    <description>The Timed Up and Go test (TUG) is a simple test used to assess a person's mobility and requires both static and dynamic balance. It uses the time that a person takes to rise from a chair, walk three meters, turn around 180 degrees, walk back to the chair, and sit down while turning 180 degrees</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analogue Scale (VAS)</measure>
    <time_frame>18th months</time_frame>
    <description>The VAS uses a straight 10 centimeter line with one end being 'no pain' and on the other end the 'worst imaginable pain'. The patient chooses a spot on the line then places a perpendicular line to indicate their pain level</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Platelet-rich plasma arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyaluronic acid arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Methylprednisolone acetate arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Platelet-rich plasma</intervention_name>
    <description>Two intra-articular injections of autologous platelets-rich plasma (PRP) in two weeks intervals between the first and the second injection.</description>
    <arm_group_label>Platelet-rich plasma arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyaluronic acid</intervention_name>
    <description>Two intraarticular injections of hyaluronic acid (60 mg) in two weeks intervals between the first and the second injection</description>
    <arm_group_label>Hyaluronic acid arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone acetate injectable suspension (DEPO-MEDROL®)</intervention_name>
    <description>Single methylprednisolone acetate intraarticular injection (DEPO-MEDROL® pfizer 80 mg) mixed with 3cc of (xylocaine 2% concentration)</description>
    <arm_group_label>Methylprednisolone acetate arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient aged 35-65 years old&#xD;
&#xD;
          -  Patient with knee pain that had been continuing for at least 12 months with no relief&#xD;
             using anti-inﬂammatory medications and that deteriorated with weight-bearing&#xD;
&#xD;
          -  Knee osteoarthritis that classified as mild-moderate or moderate-severe&#xD;
             (Kellgren-Lawrence Grade 2, 3, or 4)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 65 years&#xD;
&#xD;
          -  The recent history of knee trauma&#xD;
&#xD;
          -  Autoimmune rheumatic diseases&#xD;
&#xD;
          -  Accompanying severe hip OA&#xD;
&#xD;
          -  Thrombocytopenia or other blood diseases&#xD;
&#xD;
          -  Immunosuppressive or anticoagulant treatment&#xD;
&#xD;
          -  The invasive procedure applied to the knee&#xD;
&#xD;
          -  Intra-articular steroid injection to the knee within the previous 12 months&#xD;
&#xD;
          -  Previous joint infection&#xD;
&#xD;
          -  Uncontrolled systemic diseases such as diabetes or hypertension, and cancer&#xD;
&#xD;
          -  Excessive varus/valgus knee deformity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Usama A Al-Sari, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UOW</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wasit</name>
      <address>
        <city>Wasit</city>
        <country>Iraq</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iraq</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 7, 2021</study_first_submitted>
  <study_first_submitted_qc>July 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2021</study_first_posted>
  <last_update_submitted>July 17, 2021</last_update_submitted>
  <last_update_submitted_qc>July 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Wasit</investigator_affiliation>
    <investigator_full_name>Usama Al-Sari</investigator_full_name>
    <investigator_title>Senior Lecturer of Rheumatology M.B.,Ch.B, MSc , PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

